GlaxoSmithKline chooses not to exercise right to MET/RET/VEGFR2 inhibitor XL184

GlaxoSmithKline has decided not to exercise its option to license MET/RET/VEGFR2 inhibitor from Exelixis

Exelixis MET/VEGFR2/RET inhibitor XL184 effective in Phase I

Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis MET/VEGFR2/RET inhbitor XL184 demonstrates a 55% Response Rate and 84% Disease Control Rate in Patients with Medullary Thyroid Cancer

Amgen researchers publish discovery of RON/cMet kinase inhibitor

Researchers from Amgen have published a series of RON kinase inhibitors that demonstrates activitity in vivo and in vitro assays.

BMS publish series of Met kinase inhibitors

BMS have published a series of Pyrrolopyridine−Pyridone Based Met kinase inhibitors

Exelixis MET/RET/VEGFR2 inhibitor XL184 achieves proof of concept in cancer

Exelixis have announced that its MET/RET/VEGFR2 inhibitor XL184 has achieved proof of concept in hematologic cancers. The company has submitted data to its partner GSK who has 90 days to review the data and decide whether to exercise its option to select the compound for further development and commercialization.

Exelixis initiate Phase III trial of MET/RET/VEGFR2 inhibitor XL184 in Thyroid cancer

Exelixis have initiated a phase III trial of MET/RET/VEGFR2 inhibitor XL184 for the treatment of medullary thyroid cancer.

Exelixis begin Phase II trial of multikinase inhibitor XL184 in Glioblastoma Multiforme

Exelixis are initiating a Phase II trial of XL184 for the treatment of Malignant Glioma

Exelixis prepare for Phase III trial of its Met/Ret/VEGFR2 inhibitor XL184 in medullary thyroid cancer

Exelixis and the US FDA have reached an agreement on Phase III trial design for its Met/Ret/VEGFR2 inhibitor XL184 in medullary thyroid cancer. The trial is expected to start this summer

Amgen describe synthesis of c-Met inhibitor AMG-458

Amgen have published the synthesis and structure of c-Met inhibitor AMG-458

ArQule present ARQ-197 Phase I results

Arqule have presented results of Phase I trials of its c-Met Inhibitor ARQ 197 at ASCO. The compound was found to be safe and well tolerated